MedTrace Logo

Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms

NCT01827956 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2025-12-29

Study results available
· View outcomes & findings →

Summary

Hypothesis:

Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor activity of trastuzumab and cetuximab.

The investigators therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms may play a predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with recurrence or metastatic disease that make them inaccessible to loco regional treatment.

Conditions

  • Upper Gingival Squamous Cell Carcinoma

Interventions

DRUG

Cetuximab

Blood sample for identifying the polymorphism of FCGR3A and FCGR2A genes

Sponsors & Collaborators

  • Institut Bergonié

    lead OTHER

Principal Investigators

  • ROBERT Jacques, PU-PH · Institut Bergonié

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-08-31
Completion
2013-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827956 on ClinicalTrials.gov